Equillium Inc (EQ)
0.6842
-0.10
(-12.33%)
USD |
NASDAQ |
Nov 14, 16:00
0.6704
-0.01
(-2.02%)
After-Hours: 05:54
Equillium Research and Development Expense (Quarterly): 10.81M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 10.81M |
| March 31, 2024 | 9.743M |
| December 31, 2023 | 9.184M |
| September 30, 2023 | 8.974M |
| June 30, 2023 | 9.61M |
| March 31, 2023 | 9.272M |
| December 31, 2022 | 8.525M |
| September 30, 2022 | 8.771M |
| June 30, 2022 | 9.488M |
| March 31, 2022 | 10.76M |
| December 31, 2021 | 7.549M |
| September 30, 2021 | 6.965M |
| June 30, 2021 | 5.985M |
| March 31, 2021 | 5.88M |
| December 31, 2020 | 6.567M |
| Date | Value |
|---|---|
| September 30, 2020 | 4.218M |
| June 30, 2020 | 3.893M |
| March 31, 2020 | 4.706M |
| December 31, 2019 | 5.449M |
| September 30, 2019 | 4.182M |
| June 30, 2019 | 4.25M |
| March 31, 2019 | 3.759M |
| December 31, 2018 | 2.518M |
| September 30, 2018 | 1.222M |
| June 30, 2018 | 0.54M |
| March 31, 2018 | 0.663M |
| December 31, 2017 | 0.4824M |
| September 30, 2017 | 0.0499M |
| June 30, 2017 | 0.8014M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.893M
Minimum
Jun 2020
10.81M
Maximum
Jun 2024
7.703M
Average
8.525M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Matinas BioPharma Holdings Inc | 3.371M |
| Tenon Medical Inc | 0.708M |
| Alphatec Holdings Inc | 20.36M |
| Madrigal Pharmaceuticals Inc | 68.74M |
| Spero Therapeutics Inc | 23.72M |